🇺🇸 Rifafour in United States

46 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Pulmonary Tuberculosis — 10 reports (21.74%)
  2. Anaemia — 7 reports (15.22%)
  3. Convulsion — 5 reports (10.87%)
  4. Dyspnoea — 5 reports (10.87%)
  5. Immune Reconstitution Syndrome — 4 reports (8.7%)
  6. Blood Albumin Decreased — 3 reports (6.52%)
  7. Blood Creatinine Increased — 3 reports (6.52%)
  8. Blood Sodium Decreased — 3 reports (6.52%)
  9. Blood Urea Increased — 3 reports (6.52%)
  10. Cardiac Failure Congestive — 3 reports (6.52%)

Source database →

Other Other approved in United States

Frequently asked questions

Is Rifafour approved in United States?

Rifafour does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Rifafour in United States?

Global Alliance for TB Drug Development is the originator. The local marketing authorisation holder may differ — check the official source linked above.